United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (UTHR) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $25.1B; returns 1 day +0.5%, 1 week +10.2%, 1 year +37.8%.

United Therapeutics (UTHR) is a biotechnology company and Public Benefit Corporation (PBC) specializing in chronic, life-threatening conditions, particularly pulmonary hypertension (PH) and end-stage organ disease. Its revenue model is heavily concentrated in its treprostinil-based franchise, which accounted for approximately $2.88 billion in annual revenue as of 2024.

Groups UTHR belongs to

• Shrinking Share Count
• Biotechnology
• Buying Back Stock
• Pharmaceuticals
• Public Sector
• Rare Diseases
• Organ Transplantation
• Regenerative Medicine
• Life Sciences
• Commercial Stage Biotech
• Healthcare
• Oncology

UTHR financial model: income statement, cash flow and balance sheet